Oncology Scientific Papers
A novel Sortilin-targeted docetaxel peptide conjugate (TH1902), for the treatment of Sortilin-positive (SORT1+) triple-negative breast cancer [abstract].
2020
Cancer Res.
Marsolais C, Charfi C, Demeule M, et al.
80(16 suppl):2910. Proceedings of the Annual Meeting of the American Association for Cancer Research 2020.
A novel Sortilin-targeted docetaxel peptide conjugate (TH1902), for the treatment of Sortilin-positive (SORT1+) triple-negative breast cancer.
2020
Currie J-C, Charfi C, Demeule M, et al.
Poster #4472 presented at: Annual Meeting of the American Association for Cancer Research; June 22-24, 2020; virtual.
Sortilin receptor-mediated novel cancer therapy: A targeted approach to inhibit vasculogenic mimicry in ovarian and breast cancers [abstract].
2020
Cancer Res.
Currie J-C, Demeule M, Larocque A, et al.
80(16 suppl):865. Proceedings of the Annual Meeting of the American Association for Cancer Research 2020.
Sortilin receptor-mediated novel cancer therapy: A targeted approach to inhibit vasculogenic mimicry in ovarian and breast cancers.
2020
Demeule M, Currie J-C, Larocque A, et al.
Poster #4335 presented at: Annual Meeting of the American Association for Cancer Research; June 22-24, 2020; virtual.
Receptor-mediated chemotherapy using a new docetaxel-peptide conjugate for sortilin-positive triple-negative breast cancer [abstract].
2019
Demeule M, Charfi C, Currie J-C, et al.
80(4 suppl):P3-10-07. Proceedings of the 2019 San Antonio Breast Cancer Symposium.